- Home
- ATAT vs AKRO Comparison
ATAT vs AKRO Comparison
Compare ATAT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- AKRO
- Stock Information
- Founded
- ATAT 2013
- AKRO 2017
- Country
- ATAT China
- AKRO United States
- Employees
- ATAT N/A
- AKRO N/A
- Industry
- ATAT Hotels/Resorts
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- AKRO Health Care
- Exchange
- ATAT Nasdaq
- AKRO Nasdaq
- Market Cap
- ATAT 3.3B
- AKRO 2.8B
- IPO Year
- ATAT 2022
- AKRO 2019
- Fundamental
- Price
- ATAT $28.41
- AKRO $42.39
- Analyst Decision
- ATAT Strong Buy
- AKRO Strong Buy
- Analyst Count
- ATAT 1
- AKRO 9
- Target Price
- ATAT $36.80
- AKRO $76.29
- AVG Volume (30 Days)
- ATAT 1.7M
- AKRO 1.1M
- Earning Date
- ATAT 05-22-2025
- AKRO 05-16-2025
- Dividend Yield
- ATAT 1.59%
- AKRO N/A
- EPS Growth
- ATAT 71.91
- AKRO N/A
- EPS
- ATAT 1.26
- AKRO N/A
- Revenue
- ATAT $992,989,819.00
- AKRO N/A
- Revenue This Year
- ATAT $27.82
- AKRO N/A
- Revenue Next Year
- ATAT $22.18
- AKRO N/A
- P/E Ratio
- ATAT $21.14
- AKRO N/A
- Revenue Growth
- ATAT 55.34
- AKRO N/A
- 52 Week Low
- ATAT $15.22
- AKRO $17.86
- 52 Week High
- ATAT $33.32
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ATAT 66.61
- AKRO 52.42
- Support Level
- ATAT $24.29
- AKRO $41.60
- Resistance Level
- ATAT $25.48
- AKRO $46.47
- Average True Range (ATR)
- ATAT 1.06
- AKRO 2.05
- MACD
- ATAT 0.62
- AKRO 0.37
- Stochastic Oscillator
- ATAT 98.68
- AKRO 55.60
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.